The prognostic value of p53 for long-term and recurrence free survival following radical prostatectomy

European Journal of Cancer

Volumn 34, Issue 5, 1998, Pages 679-686

  Kuczyk, M A ^a   Serth, J ^a   Bokemeyer, C ^b   Machtens, S ^a   Minssen, A ^a   Bathke, W ^c   Hartmann, J ^b   Jonas, U ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NONE

Author keywords

p53 tumour suppressor gene; Prognostic value; Prostate cancer

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GENE EXPRESSION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032055954     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10112-5     Document Type: Article

References (32)

1. 1. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1993, 4, 7-26.
2. 2. Adolfsson J, Carstensen T, Lowhagen T. Deferred treatment in localised prostate cancer. Br J Urol 1992, 69, 183-187.
3. 3. George NJR. Natural history of localised prostate cancer managed by conservative therapy alone. Lancet 1988, i, 494-497.
4. 4. Johansson JE, Adami HO, Andersson SO, Bergström R, Holmberg L, Krusemo UB. High 10 year survival rate in patients with early untreated prostate cancer. J Am Med Assoc 1992, 267, 2191-2196.
5. 5. Voges GE, McNeal JE, Redwine EA, Freiha FS, Stamey TA. Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer 1992, 69, 520-526.
6. 6. Ackerman DA, Barry JM, Wicklund RA, Olson N, Lowe BA. Analysis of high risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 1993, 150, 1845-1850.
7. 7. Adolfson J, Steineck G, Whitmore WF. Recent results of management of palpable clinically localized prostate cancer. Cancer 1993, 72, 43-55.
8. 8. Suzuki H, Komiya A, Aida S, Ito H, Yatani R, Shimazaki J. Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer. Prostate 1996, 28, 318-324.
9. 9. Latil A, Baron JC, Cussenot O, et al. Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome arm 18q. Genes Chromosomes Cancer 1994, 11, 119-125.
10. 10. Moyret-Lalle C, Marcais C, Jacquemier J, et al. ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 1995, 64, 124-129.
11. 11. Heidenberg HB, Sesterhenn IA, Gaddipati JP, et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995, 154, 414-421.
12. 12. Mirchandani D, Zheng J, Miller GJ, et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995, 147, 92-101.
13. 13. Kubota Y, Shuin T, Uemura H, et al. Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 1995, 27, 18-24.
14. 14. Konishi N, Hiasa Y, Hayashi I, et al. P53 mutations occur in clinical, but not latent, human prostate carcinoma. Jpn J Cancer Res 1995, 86, 57-63.
15. 15. Hall MC, Navone NM, Troncoso P, et al. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 1995, 45, 470-475.
16. 16. Chi SG, deVere-White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. P53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994, 86, 926-933.
17. 17. Dinjens WN, Weiden NM van der, Schroeder FH, Bosman FT, Trapman J. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 1994, 56, 630-633.
18. 18. Navone NM, Troncoso P, Pisters LL, et al. P53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993, 85, 1657-1669.
19. 19. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. P53 is mutated in a subset of advanced stage prostate cancers. Cancer Res 1993, 53, 3369-3373.
20. 20. Mellon K, Thompson S, Charlton RG, et al. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 1992, 147, 496-499.
21. 21. Van Veldhuizen PJ, Sadasivan R, Garcia F, Austenfeld MS, Stephens RL. Mutant p53 expression in prostate carcinoma. Prostate 1993, 22, 23-30.
22. 22. Castagnaro M, Yandell DW, Dockhorn-Dworniczak B, Wolfe HJ, Poremba C. Androgenrezeptor - Gen Mutationen und p53 - Gen Analyse in fortgeschrittenen Prostatakarzinomen. Verh Dtsch Ges Pathol 1993, 77, 119-123.
23. 23. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fusks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994, 151, 1276-1280.
24. 24. Apakama I, Robinson MC, Walter NM, et al. bcl-2 over-expression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996, 74, 1258-1262.
25. 25. Brooks JD, Bova GS, Ewing CM, et al. P53 alterations do not predict recurrence in primary human prostate cancers. J Urol 1996, 155, part 2, abstr. no. 966.
26. 26. Yang G, Stapleton AMF, Wheeler TM, et al. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. J Urol 1996, 155, part 2, abstr. no. 965.
27. 27. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995, 26, 106-109.
28. 28. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivistava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J Urol 1996, 155, part 2, abstr. 552.
29. 29. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992, 84, 883-887.
30. 30. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AL. Activating mutations for transformation by p53 produce a gene product that forms an hsc-70-p53 complex with an altered half life. Mol Cell Biol 1988, 8, 531-539.
31. 31. Kuczyk MA, Bokemeyer C, Serth J, et al. P53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995, 31A, 2243-2247.
32. 32. Thomas DJ, Robinson M, King P, et al. P53 expression and clinical outcome in prostate cancer. Br J Urol 1993, 72, 778-781.